



**National Institute for
Health and Clinical Excellence**

5 August 2008

Level 1 City Tower
Piccadilly Plaza
Manchester
M1 4BD

PER EMAIL

Tel: 0845 003 7780
Fax: 0845 003 7785
Email: nice@nice.org.uk
www.nice.org.uk

Dear consultees and commentators,

**Health Technology Appraisal
Drugs for the treatment of pulmonary arterial hypertension**

In May 2008 we informed you that the timelines for the technology appraisal of drugs for pulmonary arterial hypertension had been extended because we needed more time to consider the comments we received on the appraisal consultation document.

Unfortunately, because there are still a number of outstanding issues that need to be resolved, we are not yet able to produce a final appraisal determination for this appraisal. Once we have a better idea of when we will be able to do so, we will update the timelines on the NICE website accordingly.

In the meantime, you should be aware that the National Specialised Commissioning Group (NSCG) has now endorsed the national commissioning policy approach set out in 'Target Therapies for the Treatment of Pulmonary Hypertension in Adults', which details the arrangements for access to the drugs that are subject to the technology appraisal. This will be implemented by Specialised Commissioning Groups (SCGs).

I appreciate that you may be disappointed with a further delay in the development of this technology appraisal but hope that you will appreciate that this appraisal has raised a number of complex issues that need addressing.

Yours sincerely,

Dr Carole Longson,
Director Centre for Health Technology Evaluation